Agonist stimulation of the type 5 metabotropic glutamate (mGlu5) receptor initiates robust oscillatory changes in cytosolic Ca 2ϩ concentration ([Ca 2ϩ ] i ) in single cells by rapid, repeated cycles of phosphorylation/dephosphorylation of the mGlu5 receptor, involving protein kinase C and as-yet-unspecified protein phosphatase activities. An emergent property of this type of Ca 2ϩ oscillation-generating mechanism (termed "dynamic uncoupling") is that once a threshold concentration has been reached to initiate the Ca 2ϩ oscillation, its frequency is largely insensitive to further increases in orthosteric agonist concentration. Here, we report the effects of positive allosteric modulators (PAMs) on the patterns of single-cell Ca 2ϩ signaling in recombinant and native mGlu5 receptor-expressing systems. In a Chinese hamster ovary cell-line (CHO-lac-mGlu5a), none of the mGlu5 receptor PAMs studied [3,3Ј-difluorobenzaldazine (DFB),
] i ) in single cells by rapid, repeated cycles of phosphorylation/dephosphorylation of the mGlu5 receptor, involving protein kinase C and as-yet-unspecified protein phosphatase activities. An emergent property of this type of Ca 2ϩ oscillation-generating mechanism (termed "dynamic uncoupling") is that once a threshold concentration has been reached to initiate the Ca 2ϩ oscillation, its frequency is largely insensitive to further increases in orthosteric agonist concentration. Here, we report the effects of positive allosteric modulators (PAMs) on the patterns of single-cell Ca 2ϩ signaling in recombinant and native mGlu5 receptor-expressing systems. In a Chinese hamster ovary cell-line (CHO-lac-mGlu5a), none of the mGlu5 receptor PAMs studied [3, , N-{4-chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl) methyl]phenyl}-2-hydroxy-benzamide (CPPHA), 3-cyano-N-(1, 3-diphenyl-1H-prazol-5-yl)benzamide (CDPPB), S-(4-fluorophenyl)-{3-[3-(4-fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidinl-1-yl}-methanone (ADX47273)], stimulated a Ca 2ϩ response when applied alone, but each PAM concentration-dependently increased the frequency, without affecting the amplitude, of Ca 2ϩ oscillations induced by glutamate or quisqualate. Therefore, PAMs can cause graded increases (and negative allosteric modulator-graded decreases) in the Ca 2ϩ oscillation frequency stimulated by orthosteric agonist. Initial data in rat cerebrocortical astrocytes demonstrated that similar effects of PAMs could be observed in a native cell background, although at high orthosteric agonist concentrations, PAM addition could much more often be seen to drive rapid Ca 2ϩ oscillations into peakplateau responses. These data demonstrate that allosteric modulators can "tune" the Ca 2ϩ oscillation frequency initiated by mGlu5 receptor activation, and this might allow pharmacological modification of the downstream processes (e.g., transcriptional regulation) that is unachievable through orthosteric ligand interactions.
Glutamate, the major excitatory neurotransmitter in the central nervous system, acts on ionotropic glutamate receptors to elicit fast excitatory responses and on metabotropic glutamate (mGlu) receptors to modulate and fine tune synaptic transmission (Conn and Pin, 1997) . The eight subtypes of the mammalian mGlu receptor can be divided into three subgroups, based on sequence homologies, agonist and antagonist binding profiles, and preferred coupling to signal transduction pathways. The group I mGlu receptors, mGlu1 and mGlu5, both preferentially couple via G q/11 proteins to stimulate phospholipase C activity but are differentially localized and probably fulfill distinct physiological functions (Hermans and Challiss, 2001; Mannaioni et al., 2001; Ferraguti and Shigemoto, 2006; Kumar et al., 2008) . Activation of these receptors also elicits highly distinct Ca 2ϩ responses at a single cell level, the mGlu1 receptor primarily eliciting a peak-plateau type of Ca 2ϩ response, whereas mGlu5 receptor activation leads to oscillatory changes in intracellular Ca 2ϩ concentration ([Ca 2ϩ ] i ) in both recombinant and native (e.g., astrocyte) cell backgrounds (Kawabata et al., 1996; Naka-hara et al., 1997; Nash et al., 2001 Nash et al., , 2002 Atkinson et al., 2006) .
The robust oscillatory pattern of Ca 2ϩ signaling initiated by the mGlu5 receptor has been proposed to be a result of a "dynamic uncoupling" mechanism involving rapid cycles of receptor phosphorylation and dephosphorylation (Kawabata et al., 1996) , Ser-839 being implicated most recently as the site of reversible covalent modification (Kim et al., 2005) . After agonist stimulation, the mGlu5 receptor is rapidly phosphorylated by protein kinase C, disabling productive receptor-G protein coupling (Kawabata et al., 1996; Uchino et al., 2004; Kim et al., 2005) . A protein phosphatase, perhaps tightly associated with the receptor, efficiently dephosphorylates Ser-839, allowing reactivation of the receptor, and through the rapid enabling and disabling of receptor activity, a Ca 2ϩ oscillation is generated (Nash et al., 2001 (Nash et al., , 2002 Atkinson et al., 2006 ). This mechanism is probably similar to that reported for Ca 2ϩ oscillations initiated by Ca 2ϩ -sensing receptor activation (Young et al., 2002 ), but it is clearly different from the Ca 2ϩ -induced Ca 2ϩ release mechanism proposed to explain the majority of Ca 2ϩ oscillatory behaviors elicited by (submaximal) agonist stimulation of a variety of G protein-coupled receptors (Berridge et al., 2000) .
An intriguing property of mGlu5 receptor-stimulated Ca 2ϩ oscillations is that once a concentration of agonist [e.g., glutamate, quisqualate, (S)-3,5-dihydroxyphenylglycine] has been reached to initiate a response, both the frequency and amplitude of the Ca 2ϩ oscillation is essentially insensitive to further increases in agonist concentration (i.e., an "all-ornothing" response) (Nash et al., 2002) . In contrast, altering the expression level of the mGlu5 receptor has marked effects on the frequency of the Ca 2ϩ oscillation stimulated by agonist, and Ca 2ϩ oscillation frequency can be reduced by addition of submaximally effective concentrations of the negative allosteric modulator (NAM) MPEP (1-100 nM) (Nash et al., 2002) .
Positive allosteric modulators (PAMs) of the mGlu5 receptor are thought to be of potential clinical use in a variety of neurological and psychiatric disorders, including schizophrenia (Gasparini et al., 2002; Kew, 2004) . The mGlu5 receptor is known to potentiate the function of N-methyl-D-aspartate receptors in various brain regions, and so PAMs, which bind to an allosteric site on the mGlu5 receptor and increase the response of the receptor to glutamate, may be able to counteract the N-methyl-D-aspartate receptor hypofunction proposed to be associated with this condition (Lindsley et al., 2006) . Several PAMs acting at the mGlu5 receptor have been identified, including DFB (O'Brien et al., 2003) , CPPHA (O'Brien et al., 2004) , CDPPB (Kinney et al., 2005) , and ADX47273 (Liu et al., 2008) . Like MPEP, these PAMs bind to seven-transmembrane domain of the mGlu5 receptor to modulate the effects of orthosteric agonists (Pagano et al., 2000; Malherbe et al., 2003; Mü hlemann et al., 2006) . In addition, an MPEP analog, 5MPEP, antagonizes the actions of both NAMs and PAMs at the mGlu5 receptor and thus acts as a neutral allosteric site ligand .
Considering the mechanism used by the mGlu5 receptor to generate Ca 2ϩ oscillations and the unusual emergent pharmacology, we have systematically investigated the effects of PAMs on orthosteric mGlu5 receptor agonist-stimulated responses at a single cell level. These new data add an important new dimension to previous investigations of the pharmacological properties of PAMs at the mGlu5 receptor, which to date have relied on signaling readouts that quantify cell population responses.
Materials and Methods
Compounds. L-Quisqualic acid, L-glutamic acid, 2-methyl-6-(phenylethynyl)-pyridine (MPEP) and 3,3Ј-difluorobenzaldazine (DFB) were obtained from Tocris Cookson Ltd. (Bristol, UK) . S-(4-fluoro-phenyl)-{3-[3-(4-fluoro-phenyl)-[1,2,4 ]-oxadiazol-5-yl]-piperidinl-1-yl}-methanone (ADX47273), and 5-methyl-2-(phenylethynyl)pyridine (5MPEP) were synthesized in-house by GlaxoSmithKline (Harlow, UK). 2-(2-(3-methoxyphenyl)ethynyl)-5-methylpyridine (M-5MPEP) was a kind gift from Dr. P. J. Conn (Vanderbilt Program in Drug Discovery, Nashville, TN).
Cell Culture. Chinese hamster ovary (CHO) cells expressing the human mGlu5a receptor under the control of a lac-repressor system (Hermans et al., 1998; Nash et al., 2002) were maintained in Dulbecco's modified Eagle's medium (DMEM) containing Gluta-MAX-1 with sodium pyruvate, 4.5 g/l glucose, 10% fetal bovine serum (FBS), 44 g/ml proline, 2.5 g/ml amphotericin B, 10 5 units/ml penicillin, 100 g/ml streptomycin, and 300 g/ml G418. Once confluent, flasks of CHO-lac-mGlu5a cells were washed twice with phosphate-buffered saline (without Ca 2ϩ /Mg 2ϩ ) and harvested with 0.25% (w/v) trypsin and 0.02% (w/v) EDTA. Cells were maintained at 37°C in a humidified 5% CO 2 :air atmosphere. For experiments, cells were seeded on to multiwell plates in medium with dialyzed FBS (substituted for FBS) and devoid of G418. mGlu5 receptor expression was induced by incubating CHO-lac-mGlu5a cells with 100 M isopropyl-␤-D-thiogalactoside/10 mM sodium butyrate for 24 h before experimentation.
Rat Cerebrocortical Astrocyte Preparation. Wistar rats (1-2 days of age) were decapitated, and the cortices were removed. During the dissection, cortices were placed into ice-cold Earle's balanced salt solution (EBSS; Invitrogen, Carlsbad, CA), supplemented with 3.2 mM MgSO 4 , 0.3% (w/v) BSA (fraction V), and 16.7 mM glucose. Tissue was cut up into small pieces and incubated at 37°C for 15 min in 10 ml of EBSS solution containing 0.025% (w/v) (bovine pancreatic) trypsin with gentle agitation. After 15 min, 10-ml modified EBSS solution [containing 50 M MgSO 4 , DNase I (type IV, 150 Kunitz units), and 0.02% (w/v) trypsin inhibitor] was added, and the suspension left to settle for 5 min. The supernatant was subsequently decanted, and 2.5 ml EBSS solution containing 320 M MgSO 4 , DNase I (800 Kunitz units), and 0.12% (w/v) trypsin inhibitor was added. Tissue was slowly triturated using a glass firepolished Pasteur pipette and 2.5 ml of EBSS solution [supplemented with 0.4% (w/v) BSA and 250 M MgSO 4 ] added. The cell suspension was centrifuged (1000 rpm; 8 min), and pellet resuspended in DMEM containing GlutaMAX-1 with sodium pyruvate, 4.5 mg/l glucose, 15% heat-inactivated FBS, 2.5 g/ml Fungizone, and 0.1 g/ml gentamicin. Cells were plated into poly-D-lysine-coated cell culture flasks and incubated at 37°C in a 5% CO 2 , humidified air atmosphere for 7 days, with medium being replaced after 4 days. At 7 DIV, medium was replaced again and flasks were transferred to a shaking incubator overnight (37°C; 320 rpm). On the following day (8 DIV), cells were washed twice with phosphate-buffered saline (without Ca 2ϩ /Mg 2ϩ ) and harvested with 0.25% (w/v) trypsin and 0.02% (w/v) EDTA. Cells were subsequently seeded onto precoated poly-D-lysine tissue-culture plates for experiments. After 24 h (DIV 9), medium was replaced with DMEM containing GlutaMAX-1 with sodium pyruvate, 4.5 mg/l glucose, 2.5 g/ml Fungizone, and 0.1 g/ml gentamicin and G-5 supplement. Cells were used for experiments at DIV 11 to 13.
Single-Cell Intracellular Ca 2؉ Concentration Assay. CHOlac-mGlu5a cells were seeded onto 22-mm borosilicate coverslips and grown to approximately 80% confluence. Cells were loaded with Fura-2 acetoxymethyl ester (2 M) in Krebs-Henseleit buffer (composition: 118 mM NaCl, 4.7 mM KCl, 4 mM NaHCO 3 , 1.3 mM CaCl 2 , 4 , 11.7 mM glucose, and 8.5 mM HEPES, pH 7.4) containing 1 mg/ml bovine serum albumin for 60-90 min at room temperature. Coverslips of astrocyte (DIV 11-13) were incubated with Fura-2 acetoxymethyl ester (2 M) similarly to the CHO-lac cells, except that the loading period was 40 min at room temperature. Coverslips were then transferred to the stage of an inverted epifluorescence microscope (Diaphot; Nikon, Tokyo, Japan) with an oil immersion objective (40ϫ) and a SpectraMASTER II module (PerkinElmer Life and Analytical Sciences, Waltham, MA). Cells were excited at wavelengths of 340 and 380 nm using a SpectraMASTER II monochromator, and emission was recorded at wavelengths above 520 nm. The ratio of fluorescence intensities at these wavelengths is given as an index of [Ca 2ϩ ] i . All experiments were performed at 37°C; drug additions were made via a perfusion line.
Cell Population [Ca 2؉ ] i Assay. CHO-lac-mGlu5a cells were seeded onto 96-well black-walled cell culture plates (Costar; Corning Life Sciences, Lowell, MA) and induced on the following day with isopropyl ␤-D-thiogalactoside (100 M) and sodium butyrate (10 mM) for 24 h before experimentation. Cells were loaded in Tyrode's solution containing the Ca 2ϩ sensitive fluorescent dye, calcium-3 (Calcium 3 assay kit; Molecular Devices, Sunnyvale, CA), 1.5 mM CaCl 2 , and 2.5 mM probenecid for 1 h. Allosteric modulators were preincubated for 30 min before the addition of the agonist on the FLIPR. Changes in fluorescence intensity are recorded as an index of [Ca 2ϩ ] i . Data Analysis. Concentration-response relationships were analyzed by nonlinear regression using Prism 5.0 software (GraphPad Software, San Diego, CA). For statistical tests, where only two datasets were being compared an unpaired Student's t test (two-tailed) was used, where P Ͻ 0.05 was deemed statistically significant. Where more than two datasets were compared, one-or two-way analysis of variance (ANOVA) tests were used with P Ͻ 0.05 being accepted as significantly different. ANOVA tests were followed by the Bonferroni's post hoc test. All statistical analyses were performed using Prism 5.0 software.
Results

Effects of Positive Allosteric Modulators on Ca
2؉ Oscillation Frequency. Each of the mGlu5 receptor PAMs studied, DFB, CPPHA, CDPPB, or ADX47273, caused significant (2-3-fold) increases in the frequency (but not the amplitude) of Ca 2ϩ oscillations initiated by either glutamate or quisqualate in CHO-lac-mGlu5 cells (Table 1) . Representative single cell traces are shown for the effects of DFB (100 M), CPPHA (3 M), CDPPB (10 M), and ADX47273 (10 M) on glutamate-and quisqualate-stimulated Ca 2ϩ oscillations ( Fig. 1) . To further explore how PAMs affect the Ca Effects of PAMs on the Threshold for GlutamateEvoked Ca 2؉ Oscillations. After mGlu5 receptor induction (isopropyl ␤-D-thiogalactoside/butyrate addition for 24 h), Ca 2ϩ oscillations were observed in the vast majority of Fura-2-loaded CHO-lac-mGlu5a cells challenged with either L-glutamate or quisqualate. In the presence of 1 M glutamate, only a small number of cells (Ͻ15%) responded; however, increasing the glutamate concentration to 3 M initiated baseline Ca 2ϩ oscillations in most cells (Fig. 3 , A and C) and the amplitude and frequency of the Ca 2ϩ oscillation was not significantly altered by further increases in the concentration of glutamate (3-100 M). Similar concentration-independent effects were observed for quisqualate, where 0.1 M quisqualate was sufficient to initiate Ca 2ϩ oscillations in the majority of CHO-lac-mGlu5a cells, and further increases in quisqualate concentration (0.3-10 M) did not significantly alter either the amplitude or frequency of the agoniststimulated Ca 2ϩ oscillation (data not shown). We have also evaluated the effects of DFB (30 M) on the concentration of glutamate (threshold) required to evoke Ca 2ϩ oscillations (Fig. 3B ). The presence of DFB left-shifted the threshold for the stimulation of a Ca 2ϩ oscillation by the orthosteric agonist (glutamate or quisqualate), as well as increasing the maximal oscillation frequency achieved (Fig. 3 , B and C). It should also be noted that in the presence of the PAM, it is possible to discern a more graded increase in Ca 2ϩ oscillation frequency compared with the steep, all-or-nothing glutamate concentration-response curve seen in the absence of an allosteric ligand (see Fig. 3 ; Nash et al., 2002) .
Effects of PAMs on Single-Cell Ca 2؉ Responses. Although this study focuses on Ca 2ϩ oscillatory responses, other patterns of change in [Ca 2ϩ ] i can be observed in individual CHO-lac-mGlu5a cells after agonist addition. We have undertaken analyses of Ca 2ϩ signaling patterns in CHO-lacmGlu5a (and CHO-lac-mGlu1a) cells previously (Atkinson et al., 2006) ; in that study, we classified responses into four categories [nonresponders (NR); single peak (SP), oscillatory (OS), and peak-and-plateau (PP)]. Here, we undertook similar analyses to assess how PAMs alter the occurrence of the different categories of Ca 2ϩ response. Representative data are shown for ADX47273 effects on glutamate-and quisqualate-stimulated Ca 2ϩ signaling patterns (Fig. 4) . In the absence of the PAM, orthosteric agonists stimulate a Ca 2ϩ oscillatory response in the majority (Ͼ70%) of cells, and essentially no cells show peak-and-plateau responses. After coaddition of orthosteric agonist plus ADX47273, the number of cells that are either NR or respond with only an SP diminish toward zero, whereas the number of cells driven into a PP response increases somewhat (to ϳ10-20% of all cells ana- CHO-lac-mGlu5a cells were stimulated with either L-glutamate (100 M) or quisqualate (30 M) for 300 s and then by the same concentration of orthosteric agonist plus the indicated concentration of DFB, CPPHA, CDPPB, or ADX47273. At least 20 cells were analyzed from each coverslip, and each experiment was repeated on at least 3 separate days to give the summary data shown (mean Ϯ S.E.M.). Data are shown for the number of oscillations in a 5-min period. Data were analyzed using two-way ANOVA. Fig. 4) . It is noteworthy that in both the absence and presence of the PAM, Ca 2ϩ oscillations are the predominant response seen after orthosteric agonist addition to CHO-lacmGlu5a cells.
PAMs at the mGlu5 Receptor Are Allosteric Modulators Devoid of Intrinsic Activity. None of the PAMs studied here stimulated a Ca 2ϩ response per se and required the presence of orthosteric agonist to exert their positive modulator effect (Fig. 5) . It should be noted that the medium over the CHO-lac-mGlu5a cells was rapidly exchanging throughout the time course (perfusion rate, 5 ml/min); if the perfusion rate was slowed or stopped, then a Ca oscillations in CHO-lac-mGlu5a cells (Fig. 6A) (Nash et al., 2002) , whereas the neutral allosteric modulator 5MPEP (10 M; Rodriguez et al., 2005) was without effect (Fig. 6B) . The effects of increasing concentrations of MPEP (here shown for CHO-lac-mGlu5a cells using FLIPR technology to assess population Ca 2ϩ responses) on the glutamate concentrationresponse curve illustrate the noncompetitive nature of the interaction, increasing MPEP concentrations causing a progressive suppression of the maximal response with no significant effect on the glutamate EC 50 value (Fig. 6C) . In contrast, 5MPEP was without effect on the glutamate concentrationresponse curve (Fig. 6D) .
To explore further the mechanism of action of the PAMs, we investigated whether their effects on orthosteric agoniststimulated Ca 2ϩ oscillatory responses are sensitive to the neutral allosteric antagonist 5MPEP. A representative trace illustrating the experimental design is shown in Fig. 7A . Addition of 5MPEP (10 M), after sequential additions of glutamate (100 M) and glutamate-plus-ADX47273 (10 M), caused a complete ablation of the PAM-mediated frequency increase in the glutamate-stimulated Ca 2ϩ oscillation.
Figure 7 also shows that 5MPEP could completely reverse the positive modulator effect of ADX47273, DFB, or CDPPB (Fig.  7, B-D) . In contrast, the positive modulator effect of CPPHA on glutamate-stimulated Ca 2ϩ oscillatory responses in CHOlac-mGlu5a cells was unaffected by 5MPEP (Fig. 8) .
A comparison of the effects of a positive (ADX47273), negative (MPEP), and neutral (5MPEP) allosteric modulator on orthosteric agonist-stimulated Ca 2ϩ oscillation frequency in CHO-lac-mGlu5a cells is shown in Fig. 9 . In addition, we have found that the previously reported mGlu5 receptor allosteric partial inverse agonist, M-5MPEP , also causes a concentration-dependent decrease in the glutamate-evoked Ca 2ϩ oscillations. Although this compound exhibited a lower potency with respect to inhibiting the glutamate-stimulated Ca 2ϩ response, at a sufficiently high concentration (10 M), M-5MPEP displayed a negative efficacy approaching that of MPEP (Fig. 9) .
Allosteric Modulator Effects on Glutamate-Stimulated Ca 2؉ Responses in Astrocytes. Addition of glutamate (100 M) to G5-differentiated rat cerebrocortical astrocytes initiated Ca 2ϩ oscillations that were typically of a higher frequency (Ն2 oscillations/min) than observed in the CHO-lac-mGlu5a cells and occurred on a raised baseline (Fig. 10A) . Addition of increasing concentrations of MPEP (0.01-1 M) initially reduced oscillation frequency and then completely suppressed orthosteric agonist-evoked oscillations (Fig. 10, A and B) . The potency of the MPEP-evoked suppression was pharmacologically indistinguishable from that seen previously in CHO-lac-mGlu5a cells (pIC 50 Ϸ8 M; Fig. 10B) . Likewise, the glutamate-stimulated Ca 2ϩ oscillation was completely unaffected by the neutral allosteric modulator 5MPEP (Fig. 10C ).
Similar to their effects in CHO-lac-mGlu5a cells, the PAMs investigated here possessed no intrinsic agonist activity in cerebrocortical astrocytes (data for CDPPB shown; Fig. 11A ) but were able to reduce the threshold for orthosteric agonist- evoked Ca 2ϩ responses in astrocytes. Thus, when perfused alone, glutamate (0.3 M) did not evoke a Ca 2ϩ response in the vast majority of astrocytes; however, the presence of CDPPB (10 M) resulted in the observation of Ca 2ϩ oscillations in the majority of cells (Fig. 11, C and D) .
PAMs increased the Ca 2ϩ oscillation frequency stimulated by submaximal concentrations of orthosteric agonist (Fig. 11 , G-J), whereas at maximally effective concentrations of glutamate, which already caused rapid Ca 2ϩ oscillations, addition of the PAM most often caused glutamate-mediated Ca 2ϩ oscillations to transition into sustained peak-plateau Ca 2ϩ responses (Fig. 11, I-L) . These data suggest that above a certain oscillation frequency (2-3 per minute), PAMs can drive orthosteric agonist-stimulated Ca 2ϩ oscillatory responses into peak-plateau responses.
Discussion
In the present study, we have compared and contrasted the actions of orthosteric and allosteric ligands at the mGlu5 receptor using an assay readout that allows single cell responses to be evaluated. In contrast to previous studies conducted in cell populations, these new data indicate that PAMs can uniquely affect mGlu5 receptor-mediated signal transduction in ways not achievable by orthosteric agonists alone.
Stimulation of the mGlu5 receptor has been shown to elicit robust intracellular Ca 2ϩ oscillations in astrocytes and neurons (Nakahara et al., 1997; Flint et al., 1999; D'Ascenzo et al., 2007) as well as recombinant model systems, such as the CHO-lac-mGlu5 cell-line used here (Nash et al., 2002; Atkinson et al., 2006) . Considerable evidence has accrued to support the idea that this oscillatory pattern of Ca 2ϩ signaling is brought about by a process termed "dynamic uncoupling," which involves repetitive cycles of phosphorylation and dephosphorylation of a key residue (Ser-839) in the proximal C-terminal domain of the mGlu5 receptor, which uncouple and restore signal transduction, respectively, from mGlu5 receptor to G protein (Kawabata et al., 1996; Nash et al., 2001 Nash et al., , 2002 Uchino et al., 2004; Kim et al., 2005 ). An interesting emergent pharmacological property of Ca 2ϩ oscilla- tions generated by the dynamic uncoupling mechanism is that once an orthosteric agonist concentration sufficient to initiate receptor-driven Ca 2ϩ signaling has been reached, then the frequency and amplitude of the oscillatory signal changes little over a broad agonist concentration range. This "hard wiring" of the mGlu5 receptor signaling output at a single cell level might be of physiological importance, in that it should allow an invariant signal to be maintained over a wide range of glutamate concentrations.
Here we report that four previously described mGlu5 receptor-selective PAMs (DFB, CPPHA, CDPPB, and ADX47273) all significantly increase the frequency (not the amplitude) of glutamate-or quisqualate-stimulated Ca 2ϩ oscillations in single CHO-lac-mGlu5 cells compared with stimulation with orthosteric agonist alone. None of the PAMs elicited a Ca 2ϩ response when applied to the cells in the absence of orthosteric agonist, confirming initial reports for each of the compounds that they are true allosteric modulators possessing no intrinsic agonist activity (O'Brien et al., 2003 (O'Brien et al., , 2004 Kinney et al., 2005; Le Poul et al., 2005) . At maximally effective concentrations in CHO-lac-mGlu5 cells, the PAMs caused 2-to 3-fold increases in the Ca 2ϩ oscillation frequency stimulated by a maximally effective orthosteric agonist concentration. In rat cerebrocortical astrocytes, the Ca 2ϩ oscillation frequencies observed in response to orthosteric agonist concentration were generally higher, and PAM addition could either increase Ca 2ϩ oscillation frequency further or drive the cell into a peak-plateau response (see Fig. 11 ), suggesting that above a certain frequency (ϳ3 Ca 2ϩ oscillations/min) dynamic uncoupling transitions to a different Ca 2ϩ signature in this cell background.
In CHO-lac-mGlu5 cells, CDPPB and ADX47273 caused concentration-dependent changes in the Ca 2ϩ oscillatory frequency stimulated by orthosteric agonist. (Lui et al., 2008) and functional (potentiation of Ca 2ϩ release) assays (e.g., EC 50 ϭ 0.045 M for CDPPB potentiation of the response to an EC 20 concentration of L-Glu) (Chen et al., 2007) . Furthermore, PAMs "sensitize" the mGlu5 receptor to changes in orthosteric agonist, reducing the threshold concentration of L-glutamate needed to elicit a regenerative Ca 2ϩ oscillatory response. This was demonstrated here for DFB in CHO-lac-mGlu5 cells (Fig. 3) and for CDPPB in rat cerebrocortical astrocytes (Fig. 11) . A striking feature of this sensitization is that in the presence of a PAM, Ca 2ϩ oscillations are observed in astrocytes in the presence of extracellular L-glutamate concentrations (0.3 M; see Fig.  11B ) approaching those considered to be below that required to exert excitatory actions in the CNS (Herman and Jahr, 2007) . These data suggest that mGlu5 receptor PAMs might trigger sustained Ca 2ϩ -dependent signaling at low ambient concentrations of the endogenous transmitter, as well as when extracellular glutamate is elevated by normal exocytotic release.
Therefore, mGlu5 receptor PAMs increase (and NAMs decrease; Nash et al., 2002) , the Ca 2ϩ oscillation frequency stimulated by an orthosteric agonist. This pharmacological alteration in the "hard-wired" single cell Ca 2ϩ oscillation frequency recapitulates the effects of increasing or decreasing mGlu5 receptor expression levels (through altering induction conditions in the CHO-lac-mGlu5 cell-line) (Nash et al., 2002) .
The binding sites for each of the mGlu5 PAMs have previously been characterized by other groups using site-directed mutagenesis and radioligand binding approaches. Thus, DFB and CDPPB competitively displaced binding of [ 3 H]MPEP (or a similarly radiolabeled MPEP analog) to the mGlu5 receptor and, in the case of CDPPB, this displacement was shown to be unaltered in the presence of glutamate (O'Brien et al., 2003; Kinney et al., 2005) . In addition, mutation of Ala-809 in transmembrane domain 7 of the mGlu5 receptor leads to loss of MPEP and CDPPB binding (Chen et al., 2007) . ADX47273 has also been reported to bind to the MPEP site (Le Poul et Liu et al., 2008) . In contrast, CPPHA did not displace [
3 H]MPEP binding to the mGlu5 receptor, and although mutation of alanine-809 had no effect on its PAM activity, mutation of phenylalanine-585 in transmembrane domain 1 of the mGlu5 receptor led to loss of the positive modulatory effect of this compound (Zhao et al., 2007; Chen et al., 2008) . Taken together, these previous data indicate that DFB, CDPPB, and ADX47273 exert their PAM effects by binding to the same or an overlapping site to the NAM, MPEP, but CPPHA binds to a distinct allosteric site (Conn et al., 2009 ). Here, we used the mGlu5 receptor neutral allosteric modulator 5MPEP to investigate this at a singlecell level. 5MPEP binds to the MPEP site and has been shown to block both the effects of the NAM MPEP and the PAMs DFB and CDPPB . Our initial experiments confirmed that 5MPEP had no effect on glutamate-stimulated Ca 2ϩ responses in both single-cell and cellpopulation assays. Our work clearly demonstrated that the increase in orthosteric agonist-induced Ca 2ϩ oscillation frequency caused by DFB, CDPPB, and ADX47273 was completely inhibited in the presence of 5MPEP, such that the frequency of Ca 2ϩ oscillations was reduced to that stimulated by the orthosteric agonist alone. These data provide confirmatory evidence at a single-cell level that DFB, CDPPB, and ADX47273 all exert their modulatory activities via the MPEP/5MPEP binding site on the mGlu5 receptor. In contrast, the modulatory activity of CPPHA on orthosteric agonist-stimulated Ca 2ϩ oscillation frequency was completely unaffected by the presence of 5MPEP, indicating that this PAM interacts with a distinct allosteric binding site on the mGlu5 receptor. Despite this difference in the locus of interaction of CPPHA, the activity of this PAM with respect to the modulation of glutamate-and quisqualate-stimulated Ca 2ϩ responses was indistinguishable from that of the other PAMs at a single-cell level. This contrasts with previous reports that allosteric potentiation at distinct sites of the mGlu5 receptor can result in differential effects downstream in rat cortical astrocytes (Zhang et al., 2005) .
This present work has clearly demonstrated that the frequency of Ca 2ϩ oscillations initiated by glutamate, or another mGlu5 receptor orthosteric agonist, can be concentration-dependently altered by the addition of either PAMs or NAMs in a recombinant mGlu5a receptor-expressing cell line and rat cortical astrocytes. These findings have required the study of Ca 2ϩ signaling behaviors using single-cell assays and suggest that at this level, PAMs and NAMs primarily mediate frequency rather than the amplitude modulation of the Ca 2ϩ signal. Alteration of the Ca 2ϩ oscillation frequency can have a number of (patho)physiological consequences, because changes in the frequency of Ca 2ϩ oscillations have previously been shown to influence the activation of specific Ca 2ϩ -dependent enzymes (De Koninck and Schulman, 1998), the synthesis and release of various gliotransmitters (Agulhon et al., 2008) and growth factors (Jean et al., 2008) , and gene transcriptional activation patterns (Dolmetsch et al., 1998; Tomida et al., 2003) . Therefore, the ability of mGlu5 receptor PAMs to alter the frequency of Ca 2ϩ oscillations in single cells has the potential to alter fundamentally the cell's interpreta- . Mean data are shown as the percentage of the total number of cells analyzed that gave NR, SP, OS, or PP response for each condition. These latter data are determined from analysis of least 50 individual astrocytes over at least three separate experiments. Note that CDPPB reduced the threshold for glutamate-stimulated Ca 2ϩ oscillations (C), and although this PAM increased oscillation frequency at low orthosteric agonist concentrations (E, F and G, H), it transformed the response from oscillatory to peakplateau at high agonist concentrations (I, J and K, L).
tion of the signal initiated at the cell surface. This will require a reevaluation of how allosteric modulators are to be used to manipulate mGlu5 receptor signaling in a variety of central nervous system disorders, including schizophrenia (Conn et al., 2009 ).
